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oral administration of 12 mg of diltiazem per kg of rat with 
multiple dose co-administration of 20 mg/kg piperine 
Appendix 6.4 (b) Plasma diltiazem concentration values of individual rats after 179 
oral administration of 12 mg of diltiazem per kg of rat without 
multiple dose co-administration of 20 mg/kg piperine 
Appendix 6.5 (a) Plasma rifampicin concentration values of individual rats after 180 
oral administration of 10 mg of rifampicin per kg of rat with 
single dose co-administration of 20 mg/kg piperine 
Appendix 6.5 (b) Plasma rifampicin concentration values of individu_al rats after 180 
oral administration of 1 0 mg of rifampicin per kg of rat without 
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Appendix 6.6 (a) Plasma rifampicin concentration values of individual rats after 181 
oral administration of 10 mg of rifampicin per kg of rat with 
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oral administration of 10 mg of rifampicin per kg of rat without 
multiple dose co-administration of 20 mg/kg piperine 
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PENGARUH INTERAKSI MAKANAN DAN DRUG TERHADAP BIOKEPEROLEHAN 
DRUG ORAL 
ABSTRAK 
Kajian in dijalankan untuk mengkaji potensi interaksi di antara juzuk makanan umum 
(capsaicin; kafein; piperine} dan drug yang merupakan substrat kepada P-glikoprotein 
(P-gp} dan/atau Sitokrom P450 subfamili CYP3A (CYP3A}. Capsaicin dijumpai dalam 
buah Capsicum ( cili), manakala kafein dijumpai dalam pelbagai makanan dan minuman 
seperti kopi, di samping itu piperine adalah alkaloid utama daripada lada. Diltiazem dan 
rifampicin yang merupakan substrat kepada kedua-dua P-gp dan CYP3A telah 
digunakan sebagai drug model. Dua kaedah kromatografi cecair prestasi tinggi yang 
mempunyai kespesifikan dan sensitif telah berjaya dibangunkan untuk menentukan 
kepekatan kedua-dua sebatian tersebut dalam plasma tikus/manusia. Kedua-dua 
kaedah juga mempunyai kejituan dan kepersisihan yang bagus. 
Semua ujikaji dijalankan mengikut rekabentuk bersilang dua-hala dengan menggunakan 
tikus Sprague-Dawley, yang mana kedua-dua drug diberi bersama atau tanpa juzuk 
makanan. Pengaruh setiap juzuk makanan dikaji dengan diberi sebagai satu dos dan 
juga dos berulang selama 7 hari. Dalam ujikaji satu dos, drug model diberi setengah 
jam selepas diberi juzuk makanan manakala dalam ujikaji dos berulang, drug model 
diberi setengah jam selepas dos terakhir bagi juzuk makanan. Dos-dos diltiazem, 
rifampicin, capsaicin, kafein dan piperine yang diberi kepada tikus adalah berdasarkan 
berat badan tikus iaitu 12, 10, 4, 6 dan 20 mg/kg masing-masing. Dalam ujikaji 
capsaicin, tidak ada peningkatan signifikan (p>0.05) dalam biokeperolehan untuk 
kedua-dua diltiazem dan rifampicin apabila tikus diberikan satu dos ataupun 7 dos 
berulang setiap hari, walaupun biokeperolehan didapati meningkat sebanyak 1.1 dan 
1.2 kali masing-masing. Namun demikian, dalam kes dengan kafein, takat penyerapan 
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diltiazem dan rifampicin adalah didapati meningkat secara signifikan (p<O. 05) sebanyak 
1.4 dan 1.5 kali masing-masing apabila diberi bersama satu dos kafein. Dalam dos 
berulang dengan kafein, biokeperolehan kedua-dua drug model juga didapati meningkat 
secara signifikan (p<0.05) sebanyak 1.4 dan 1.3 kali masing-masing. Yang menariknya, 
di dalam satu ujikaji yang berasingan di mana tikus diberikan kafein sahaja sebanyak 7 
dos, biokeperolehannya yang didapati selepas dos terakhir adalah berkurangan secara 
signifikan (p<0.05) jika dibandingkan dengan yang didapati selepas dos pertama. 
Walaubagaimanapun, tidak ada perbezaan yang signifikan .. (p>0.05) pada 
biokeperolehan yang diperolehi apabila hanya dua dos berasingan yang diberikan 
dengan diperantarakan sebanyak 6 hari. Walaupun demikian, kedua-dua dos sekali dan 
dos berulang dengan kafein didapati masih mempengaruhi biokeperolehan kedua-dua 
drug yang merupakan substrat kepada P-gp dan CYP3A secara signifikan. 
Untuk piperine, walaupun ia sudah dihakciptakan sebagai perangsang biokeperolehan, 
tidak ada peningkatan signifikan (p>0.05) dalam biokeperolehan yang didapati untuk 
kedua-dua diltiazem dan rifampicin dalam kajian ini, tanpa mengira piperine diberikan 
dalam satu dos ataupun dos berulang. Dengan itu, kegunaannya sebagai perangsang 
biokeperolehan masih ada kontroversi. 
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EFFECT OF FOOD-DRUG INTERACTION ON ORAL DRUG BIOAVAILABILITY 
ABSTRACT 
The present study was conducted to investigate potential interactions between some 
common food constituents (capsaicin; caffeine; piperine) and substrate drugs of P-
glycoprotein (P-gp) and/or Cytochrome P450 subfamily CYP3A (CYP3A). Capsaicin is 
found in Capsicum fruits (chillies), whereas caffeine is found in many common food and 
beverages like coffee while piperine is a major alkaloid from pepper. Diltiazem and 
rifampicin, which are known substrates of both P-gp and CYP3A, were used as model 
drugs. Two high-performance liquid chromatographic (HPLC) methods with the required 
specificity and sensitivity were successfully developed for determination of the two 
respective compounds in rat/human plasma. Both methods also possessed good 
precision and accuracy. 
All studies were carried out according to a 2-way crossover study design using Sprague-
Dawley rats, where both drugs were administered with and without co-administration of 
each food constituent. The influence of each food constituent was studied by giving it as 
a single dose as well as 7 daily doses. In the single dose study, the model drugs were 
given half an hour after the food constituent while in the multiple dose study, they were 
given half an hour after the last dose of the food constituent. The respective doses of 
diltiazem, rifampicin, capsaicin, caffeine and piperine used were 12, 10, 4, 6 and 20 
mg/kg body weight of the rats. 
In the study with capsaicin, no significant increase (p>0.05) in bioavailability was 
observed with both diltiazem and rifampicin when the animals were treated with either a 
single capsaicin dose or 7 daily consecutive doses, although their bioavailability were 
found to be slightly increased by 1.1 and 1.2 times, respectively. However, in the case of 
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caffeine, the extent of absorption of diltiazem and rifampicin was found to be 
significantly increased (p<0.05) by 1.4 and 1.5 times, respectively when co-administered 
with a single caffeine dose. On multiple caffeine administration, the bioavailability of the 
two model drugs was also found to be significantly (p<0.05) increased by 1.4 and 1.3 
times, respectively. Interestingly, in a separate study where the rats were given 7 daily 
doses of caffeine alone, its bioavailability determined after the last dose was found to be 
significantly reduced (p<0.05) compared to that determined afte_r the first dose. 
However, no significant difference (p>0.05) in bioavailability was observed when only 
two doses were given 6 days apart. Nevertheless, both single and multiple dose 
administration of caffeine were found to significantly alter the bioavailability of the two P-
gp and CYP3A substrate drugs. 
As for piperine, even though it has been patented as a bioavailability enhancer, no 
significant increase in bioavailability (p>0.05) was observed with both diltiazem and 
rifampicin in the present study, whether piperine was given as a single dose or in 
multiple doses. Thus, its utility as a bioavailability enhancer is controversial. 
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CHAPTER 1 
INTRODUCTION 
1.1 General Introduction 
Bioavailability refers to the rate and extent of an administered dose of a drug which 
reaches the systemic circulation intact (Ashford, 2002a). To date, the major and most 
preferred way of delivering drugs to systemic circulation is still via the oral route as it is 
safer, more efficient and more easily accessible with minimal discomfort to the patients 
compared to other routes of drug administration (Petri and Lennernas, 2003}. 
It has been well established that bioavailability of orally administered drugs can be 
influenced by various factors such as the physiological conditions of the gastrointestinal 
tract, physicochemical properties of the drug as well as formulation factors, In recent 
years, extensive research on drug-drug interactions has revealed the immense impact 
of the previously unknown transporters and enzymes in the enterocytes of the 
gastrointestinal tract on the oral bioavailability of drugs with varied characteristics 
(Mizuno eta/., 2003; Chan eta/., 2004). Further investigations even uncovered that food 
and herb constituents were capable of modulating the transporters as well as the 
enzymes, hence affecting the oral bioavailability of concomitantly administered drugs 
(Deferme and Augustijns, 2003; Goosen eta/., 2004). 
1.2 Drug transport across cell membranes 
Following oral administration, drug molecules have to dissolve in the gastrointestinal 
fluid and cross the gastrointestinal membrane in order to be channelied via the hepatic 
portal vein to the liver before gaining access into the systemic circulation. Moreover, 
they must be absorbed adequately and efficiently in order to exert satisfactory 
therapeutic effects. Nevertheless, before reaching the portal circulation, dissolved drug 
molecules have to penetrate the mucous layer, the apical cell surface, the fluid within 
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the cell, the basolateral membrane, the basement membrane, the external capillary 
membrane, the cytoplasm of the capillary and finally the inner capillary membrane 
(Ashford, 2002b). 
A schematic diagram of pathways mediating the transmembrane transport cited from 
Hamalainen and Frosteii-Karlsson (2004) is shown in Figure 1.1. Drug transport across 
the biological membrane occurs via two main routes, namely the paracellular and the 
transcellular pathways. Mechanisms involved in drug transport will be further discussed 
in the following sections. 
Apical 
side 
Paracellular 
Basolateral 
side 
Transcellular 
Majority of 
compounds 
Carrier-
mediated 
Endocytosis 
Figure 1.1 Mechanisms in membrane permeation 
1.2.1 Paracellular pathway 
Efflux 
Metabolism 
The paracellular pathway involves passage of small molecules and water soluble 
substances such as urea, through the aqueous pores between the epithelial cells by 
simple diffusion. This pathway is especially important for transport of sugars and ions 
such as calcium at concentrations above the capacity of their carriers (Ashford, 2002b). 
Also, transport of compounds via this pathway is greatly influenced by molecular weight, 
transport volume and molecular charge (Ungell and Karlsson, 2003). 
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The poor absorption of compounds transported through the paracellular pathway is 
mainly attributed to the much smaller surface area presented by the pores compared to 
that of the membrane, limited dimension of the pore as well as restriction by the tight 
JUnction along the apical membrane surface (Smith et a/., 2001 ). Moreover, the 
intercellular spaces occupy only about 0.01% of the total surface arec;i of the epithelium 
(Ashford, 2002b). Generally, the molecular weight cut-off values for transport via this 
pathway in the small and large intestines are approximately 400 g/mol and 300 g/mol, 
respectively (Ungell and Karlsson, 2003). Thus, as the number and size of the pores 
between the epithelial cells decrease along the gastrointestinal tract, the contribution of 
this pathway to drug absorption also becomes negligible at the more distal part of the 
gastrointestinal tract. 
1.2.2 Transcellular pathway 
Transport of molecules across the biological membrane via transcellular pathway is 
regarded as the main route of absorption for many drugs. The transcellular pathway 
involves transport of relatively large molecules (above 200 Da) across biological 
membrane via simple passive diffusion, carrier-mediated transport and vesicular 
transport (Ashford, 2002b). 
1.2.2.1 Passive diffusion 
Passive diffusion is a process driven by a concentration gradient (activity gradient) 
(Mayersohn, 2002). Drug molecules diffuse from the region of high <;oncentration (e.g. 
gut lumen) to that of low concentration (e.g. blood capillary). The rate of drug transport 
is governed by the physicochemical properties of the drug, the nature of the membrane 
and the concentration gradient across the membrane. Often, passive diffusion across 
the gastrointestinal membrane is expressed mathematically according to Fick's first law 
of diffusion which states that diffusion rate R (in moles s-1) is proportional to the 
concentration gradient dC/dX: 
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R=-DAdC 
dX 
(1.1) 
Where dC is the concentration difference between the outside and inside of the 
membrane, and dX is the thickness of the membrane. A is the area of membrane over 
which diffusion occurs, and D is a constant (for specific molecule in a specific 
environment) called diffusion coefficient (Washington et a/., 2001 a). It is apparent from 
Equation (1.1) that the rapid rate of passive diffusion is attributed to targe surface area 
which indicates that the small intestine is the major site of drug absorption, owing to the 
presence of the large number of villi and microvilli (Ashford, 2002b). In addition, 
enhanced transport of drug molecules via passive diffusion can also be achieved by 
increasing the concentration gradient as well as selecting a drug molecule with higher D 
value (Washington eta/., 2001a). 
There are two main factors governing the diffusion coefficient (D), namely, the solubility 
and molecular weight of the drug. The relative solubility of a drug molecule in aqueous 
or oily environment is expressed using the logarithm (log) of the partition coefficient, P, 
which describes the extent of the drug distribution between a pair of solvents (usually 
water and an oily solvent such as octanol) (Washington et a/., 2001 a). Molecules with 
very low log P values are known to be hydrophilic, and hence difficult to dissolve in the 
lipid bilayer of the gastrointestinal membrane. On the contrary, molecules with very high 
log P values are too lipophilic to dissolve in the extracellular fluid or have too strong 
affinity with the lipid bilayer, causing a phenomenon known as solubility-limited 
absorption (Washington et a/., 2001a). Therefore, a drug needs to have sufficient 
lipophilicity in order to partition into the membrane, yet sufficiently s.oluble in aqueous 
environment so that it can dissolve in gastrointestinal fluid and also partition out of the 
membrane readily into the blood circulation. 
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Apart from solubility, molecular weight of a drug was also found to influence the diffusion 
coefficient. In general, drugs with a smaller molecular weight but similar log P values will 
diffuse faster across the membrane than those with a larger molecular weight 
(Washington eta/., 2001 a). 
1.2.2.2 Carrier-mediated transport 
Although majority of drugs are transported through passive diffusion, carrier-mediated 
transport has been found to play a vital role in transporting certain drugs as well as 
nutrients from the gastrointestinal lumen across the epithelial cells. There are two main 
carrier-mediated transports, namely active transport and facilitated diffusion or transport 
(Ashford, 2002b). In carrier-mediated transport, a drug-carrier complex forms at the 
apical side of the membrane and the complex subsequently moves across the cell 
membrane to release the drug into the other side of the membrane. The carrier then 
returns to its initial position to form a complex again with another drug molecule or other 
compounds to sustain the process. A schematic diagram of carrier-mediated transport is 
shown in Figure 1.2. 
Intestinal 
lumen Cell interior 
__ .,. 
I Drug + Carrier --l 
I I 
I I 
I I 
I + Drug 
--+ Carrier Carrier --+Drug 
t I 
I I 
I I 
I I L __ Carrier I ~--
Figure 1.2 Diagrammatic representation of carrier-mediated transport of a drug across a 
cell membrane (Ashford, 2002b) 
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1.2.2.2.1 Active transport 
In contrast to passive diffusion, active transport is characterised by transport of drug 
molecules against the concentration gradient that is from a region of low concentration 
to that of high concentration. Therefore, it is an energy-consuming process (Shargel and 
Yu, 1985) and the energy is derived from either the hydrolysis of intracellular adenosine 
triphosphate (A TP) or the transmembranous sodium gradient and/or electrical potential 
(Washington eta/., 2001a; Ashford, 2002b). 
Various nutrients such as amino acids, sugars, electrolytes, vitamins and bile salts as 
well as peptide-like drugs such as the penicillins, cephalosporins, angiotensin-
converting enzyme (ACE) inhibitors and renin inhibitors are actively carried by 
transporters in the small intestine, present on either the apical (brush border) or the 
basolateral membrane (Shin eta/., 2003). Transporters involved as either influx or efflux 
pumps involved in the active transport process will be further detailed in section 1.4. 
Unlike passive diffusion whereby the rate of absorption is directly proportional to the 
concentration of the absorbable species of the drug at the absorptive site, the rate of 
drug absorption in active transport is only proportional to the drug concentration at 
relatively low concentrations. At higher drug concentrations, the carriers can become 
saturated and further increases in drug concentration will not increase the rate of 
absorption (Ashford, 2002b). 
1.2.2.2.2 Facilitated diffusion or transport 
As facilitated diffusion or transport carries drugs across the membrane along a 
concentration gradient, it does not require energy input (Shargel and Yu, 1985). 
However, as carriers are also involved, the transport is therefore saturable and 
selective. Besides being saturable, the rate of facilitated diffusion is also affected by 
molecular weight as well as polarity of the molecule. Furthermore, it shows competitive 
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kinetics for drugs of similar structures like the active transport system (Shargel and Yu, 
1985). However, facilitated diffusion seems to play a very minor role in drug absorption 
(Ashford, 2002b). 
1.2.2.3 Vesicular transport 
Membrane transport via diffusion or transporters is only viable for small molecules. 
Large molecules such as macromolecules and particles are internalised by a completely 
different mechanism in which a portion of the membrane extends and envelops the 
object. drawing it into the cell to form a vacuole. This process is known as cytosis 
(Washington eta/., 2001a). Endocytosis is the process in which the membrane surface 
invaginates and pinches off, creating small intracellular vesicles that enclose a volume 
of material. These compounds will then be transferred to either other vesicles or 
lysosomes that will digest the vesicles. Materials that manage to escape the digestion 
migrate to the basolateral surface of the cell where it is exocytosed. Enterocytes, (the 
cells lining the epithelium of the gastrointestinal tract) also possess vesicular transport 
process facilitating drug absorption (Hidalgo, 2001) which includes fluid-phase 
endocytosis (FPE) or pinocytosis, receptor-mediated endocytosis (RME), phagocytosis 
and transcytosis. 
Pinocytosis or FPE involves engulfment of small droplets of extracellular fluid by 
membrane vesicle. Fat soluble vitamins A, D, E and K as well as some peptides and 
proteins are absorbed via this slow process (Hidalgo, 2001; Ashford, 2002b). Receptor-
mediated endocytosis is usually meant only for the mucosal permeation of 
macromolecules, but not small molecules. Receptors on the membrane have the 
capability to bind with some ligands followed by clustering of the receptor-ligand 
complex into clathrin-coated pits (Hidalgo, 2001 ). The receptors will then dissociate from 
the ligands in the endosomes and be recycled back into the plasma membrane. 
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Phagocytosis involves engulfment of particles larger than 500 nm by the cell membrane 
to form a phagosomes whereas transcytosis is a mechanism in which a cell encloses 
extracellular material in an invagination of the cell membrane to form a vesicle, then 
moves the vesicle across the cell to eject the material through the opposite cell 
membrane by the reverse process (Ashford, 2002b). The most common phagocytotic 
process occurs when white blood cells (macrophage) engulf foreign compounds such as 
viruses and bacteria. This process is also very important for absorption of vaccines from 
the gastrointestinal tract (Washington eta/., 2001a; Ashford, 2002b). 
1.3 Oral drug absorption from the gastrointestinal tract 
The gastrointestinal tract (GIT) is a highly specialised region of the body which is 
involved in the processes of secretion, digestion and absorption. The GIT consists of 
three major anatomical regions, namely the stomach, small intestine and large intestine 
(colon). As mentioned earlier, oral administration is the most convenient and frequently . 
used route of drug administration. Drugs in oral dosage form have to be absorbed from 
the GIT before entering the systemic circulation via the portal vein to exert therapeutic 
effects. As drugs descend through regions of the GIT, numerous factors such as 
different pH environment, enzymes, electrolytes, fluidity and surface ... features can limit 
the rate and extent of intact drug entering the systemic circulation. 
1.3.1 The stomach 
Stomach is the preparative as well as primary storage region of the GIT. It acts as a 
reservoir which processes food into fluid chyme to facilitate nutrient absorption from the 
small intestine and controls the rate of nutrient delivery to the small intestine. The 
stomach can be divided into two major regions, i.e. the fundus and body that make up 
the proximal region, and the antrum and pylorus that make up the distal region. 
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Since ingested food is not sterile, stomach produces acid which has bacteriostatic 
activity. Besides that, the acid also helps to adjust the gastric pH to an appropriate level 
for pepsin to function (Washington eta/., 2001b). The surface of stomach, namely the 
mucosa (mucous membrane), is lined with a single layer of simple columnar epithelium 
which is protected from the acidic environment by a layer of thick mucus secreted by the 
columnar cells. This mucus also lubricates food masses and facilitates movement of 
food within the stomach (Washington et a/., 2001 b). Gastric pH is influenced by acid 
secretion as well as gastric content, and is not uniform within the stomach. 
When an orally administered drug reaches the stomach, it is exposed to a highly 
variable environment in terms of food content and pH. Thus, the oral bioavailability can 
be affected by rate of gastric emptying, the presence of food or other~rugs, the dosage 
form as well as the drug carrier (Washington eta/., 2001 b). 
The time taken for a dosage form to traverse the stomach is often expressed as the 
gastric residence time, gastric emptying time or gastric emptying rate (Ashford, 2002b). 
As drug absorption occurs mainly in the small intestine, the duration of drug residence in 
the stomach can influence the rate as well as the extent of drug absorption. Apart from 
that. the longer the drug remains in the stomach, the higher the chance of it being 
exposed to the highly acidic environment and the enzymes of the stomach that might 
cause drug degradation. Often, factors that cause variability in gastric .. emptying rate are 
complex and multidimensional, and these include the type of dosage form, presence of 
food. disease state, viscosity of gastric content, emotional state and postural position. 
In general, an oily meal may delay the gastric emptying time, thus the drug absorption. 
However, the extent of food facilitating drug absorption also depends on other factors 
such as the physicochemical properties of the drug, dose, dosage form, time of drug 
administration relative to food intake, amount and type of food ingested (Mayersohn, 
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2002). Posture after oral drug administration was also found to affect the drug 
absorption. For example, lying down decreased the rate of gastric emptying compared 
to sitting upright whereas combination of sitting and standing was found to produce the 
most rapid rate of gastric emptying. It was reported that administration of 
acetaminophen and nifedipine resulted in greater plasma concentrations when given to 
subjects lying on their right or standing compared to those lying on their left (Renwick et 
a/., 1992; Washington et al., 2001b; Mayersohn, 2002). 
1.3.2 Small intestine 
The small intestine is the longest section of the GIT, comprising of 3 regions, namely the 
duodenum (200-300 mm), the jejunum (2 m) and the ileum (3 m), and is most essential 
in drug and nutrient absorption. The surface of small intestine which consists of fold of 
Kerkring (folding of the epithelium, projecting into the lumen), villi (finger-like projections 
of epithelial surface) and microvilli (apical brush border membrane of the enterocytes) 
provides a relatively large surface area· for absorption within the small abdominal volume 
(Washington eta/., 2001c). The surface area of the small intestine is increased by about 
600 times compared to that of a simple cylinder of similar dimension due to the 
presence of these special structures. 
The intestine has diverse functions which range from the mediation of the absorption of 
nutrients, waters and electrolytes, to the filtration of the foreign toxic compounds out of 
the body. In this regard, the intestinal epithelium is equipped with a complex structure of 
various types of cells such as the goblet cells, endocrine cells, tuft or calveolated cells 
and the absorptive cells (Washington eta/., 2001c). The most common type of epithelial 
cells is the absorptive cells or the enterocytes. The enterocytes are tall and columnar in 
shape, lining the epithelium to form a continuous single-celt thick surface, and are 
structurally supported by lamina propria (consisting of blood vessels, lymph and nerves). 
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Compounds must be able to cross the enterocytes to gain entry into the lamina propria 
in order to be absorbed into the bloodstream. 
However, before reaching the enterocytes, several features of the intestinal epithelium 
not only inhibit the uptake of drug molecules, but also facilitate drug elimination by 
expelling them back into the lumen. The unstirred water layer or aqueous boundary 
layer refers to the stagnant layer of water, mucus and glycocalyx (a web of branching 
which is formed by a layer of mucopolysaccharides) adjacent to the intestinal wall 
(Ashford, 2002b). This mucus layer serves as barrier to drug diffusrbn by complexing 
with some drug molecules hence impeding drug absorption. Another restriction by 
epithelial cells in controlling molecule uptake can be represented by the tight junction. 
Apically located tight junctions limit paracellular transport especially compounds with 
molecular weights of more than 200 Da (Ashford, 2002b). 
Absorption of certain essential substances is facilitated by the presence of selective 
influx transport proteins in the enterocytes, such as the amino acid and monosaccharide 
transporters (van Asperen et a/., 1998a). However, there are also efflux mechanisms 
located in the apical membrane of the enterocytes which counter-transport a broad 
range of structurally unrelated compounds back into the gastrointestinal lumen, and 
hence, limiting the oral bioavailability of many drugs. P-glycoprotein (P-gp) is the most 
studied member of apical efflux transporters, which belongs to the multidrug resistance 
(MDR) subfamily (Higaldo, 2001 ). Other apical membrane efflux transporters include the 
multidrug resistance-associated protein (MRP) and breast cancer-resistance protein 
(BCRP) families. 
In addition to transporters, another biochemical barrier to drug absorption is the drug-
metabolising enzymes. Almost all the drug-metabolising enzymes present in the liver 
are also found in the small intestine but at much lower levels (Peters and Kremers, 
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1989; Shimada et at., 1994). The existence of cytochrome P450 superfamily enzymes in 
the enterocytes of the small intestine becomes critical when more than 50% of drugs are 
recognised to be substrates of these enzymes (Wacher et at., 1995) ... Both transporters 
and enzymes may contribute significantly to poor oral drug bioavailability and their 
interactions will be further discussed in section 1.4 and 1.4.3, respectively. 
1.3.3 Large intestine 
The large intestine or often referred to as the colon, has two major functions, i.e. to 
absorb water and electrolytes as well as to store faecal material before elimination 
(Mayersohn, 2002). It is structurally similar to the small intestine but is lacking in the 
special feature, villi. Functionally, colon can be differentiated into two parts, the proximal 
segment (which includes the caecum, ascending colon and portions of the transverse 
colon) primarily for absorption; and the distal segment (which includes the transverse 
and descending colon, the rectum as well as the anus, terminating at the internal anal 
sphincter) which is mainly concerned for storage and mass movement of faecal 
materials (Mayersohn, 2002). 
The colon is found to be permanently colonised by massive amount of different bacteria 
flora. Enzymes produced by the large colony of bacteria are capable of performing 
several metabolic reactions, including hydrolysis of fatty acid esters and reduction of 
inactive conjugated drugs to their active forms (Ashford, 2002b). Of late, much interest 
has been prompted in utilising these enzymes for drug targeting in the colon 
(Washington et at., 2001d). 
Major problems of colonic absorption are reduced surface area, wide lumen, sluggish 
movement, low volume of available dissolution fluid and reduced permeability of the 
colonic epithelium to polar compounds (Washington et at., 2001d). In addition, gas 
bubbles present in the colon also reduce drug contact with mucosa of the large 
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intestine. However, colon is thought to provide a good environment, such as mild pH, 
little enzymatic activities, long transit time and no documented active transporters for 
drug absorption (Washington eta/., 2001d; Mayersohn, 2002). There are indeed active 
interests in delivery of drugs, especially peptides, to the colon for site-specific absorption 
by preventing release of drug from the dosage form before reaching the colon (Friend, 
1991 ). 
1.4 Role of transporters and metabolising enzymes in small intestine on oral drug 
bioavailability 
Apart from the physical barrier of the GIT that can affect the oral bioavailability of drugs 
and nutrients, it is now well recognised that the enterocytes of the GIT, especially the 
small intestine, express a variety of transporters as well as metabolising enzymes. Many 
water-soluble compounds that include peptide analogues, nucleosides, amino acids, 
sugars, monocarboxylic acids, bile acids, fatty acids, organic cations and anions, 
phosphates and water-soluble vitamins are able to cross biological membranes via 
specialised carrier-mediated transport mechanisms (Shin eta/., 2003). It has now been 
discovered that these transporters are one of the determinant factors governing the 
pharmacokinetics of orally administered drugs (Ishikawa et a/., 2004). While influx 
transporters mediate absorption of drug molecules or nutrients through specialised 
carrier-mediated transport, there are also efflux transporters which on the other hand, 
extrude them out of the cells and back into the gastrointestinal lumen. There is a variety 
of transporters highly expressed in human intestine. Figure 1.3 shows the selected 
important transporters localised in the intestine epithelium as reviewed by Kruijtzer eta/. 
(2002). 
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Localisation of selected transporters expressed in intestinal epithelial 
cells. (BCRP=breast cancer-resistance protein; MRP1-5=multidrug 
resistance protein family; P-gp=P-glycoprotein; PEPT1 =oligopeptide 
transporter 1; CYP3A=metabolising enzyme belonging to Cytochrome 
P450 superfamily) 
To date, many influx transporters expressed in the small intestine have been identified; 
these include peptide transporter, amino acid transporter, nucleoside transporter and 
glucose transporter. Among these transporters, intestinal oligopeptide transporter or di-
/tripeptide transporter (PEPT1) has been most extensively studied and recognised in 
relation to mediating transport of many peptide-like drugs (Tsuji, 2002.; Terada and lnui, 
2004). PEPT1 is a proton coupled transporter that is known to play an essential role in 
the oral absorption of angiotensin-converting enzyme (ACE) inhibitors, renin inhibitors, 
antitumour drugs, thrombin inhibitors and a dopamine receptor antagonist (Rubio-Aiiaga 
and Daniel, 2002). Other influx transporters such as amino acid transporters and 
nucleoside transporters also have been utilised for improving oral drug absorption. 
Amino acid analogues including L-4-chlorokynurenine, abapentin, baclofen and 
gabapentin are thought to be carried by amino acid transporters while nucleoside 
analogues such as azidothymidine, zalcitabine, cladribine and cytorabine depend on 
nucleoside transporters to be taken up across the epithelial cells (Shin· eta/., 2003). 
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Apart from influx transporters, known efflux transporters that are expressed in the 
epithelial cells of intestine include the multidrug-resistance protein (MDR), multidrug 
resistance-associated protein (MRP) and breast cancer-resistance protein (BCRP). 
These three transport proteins belong to the ABC (ATP-Binding Ca$Sette) superfamily 
and are classified as the primary active efflux transporters. ABC superfamily is a large 
group of proteins comprising of membrane transporters, ion channels and receptors 
which show general sequence and structural homology (Higgins, 1992). These efflux 
transporters mediate cellular efflux in an active ATP-dependent manner against 
concentration gradient (Dietrich et a/., 2003). General structure of ABC transporters 
consists of 12 transmembrane regions, which are split into two 'halves', with each 'half 
having a nucleotide binding domain. The exception is the ABC White subfamily, which is 
also known as 'half-transporters'. The half-transporters only have 6 transmembrane 
regions with the sole nucleotide binding domain (Hyde eta/., 1990).· ABC transporters 
are primarily expressed in the brush border membrane of the enterocytes, where a 
variety of structurally diverse drugs; drug conjugates or metabolites and other 
compounds are extruded out of the cell, thus limiting the ultimate amount of drugs 
absorbed (Hunter eta/., 1993; Ambudkar eta/., 1999). 
The MRP family of proteins has been shown to extrude organic anions including their 
conjugated metabolites, out of the cells (Konig eta/., 1999). MRP1 together with MRP3 
and MRP5 are localised at the basolateral membranes of the epi~helial cells, while 
MRP2 and MRP4 are expressed on the apical membranes (BOehler eta/., 1996; Peng 
et a/., 1999; Mottino et a/., 2000). To date, the role of MRP1 in mediating drug 
disposition has yet to be recognised. However, the presence of MRP1 did demonstrate 
its ability to confer drug resistance in a range of cancer cell lines, which contributes to 
drug resistance and might therefore, influence overall drug disposition. Meanwhile, of all 
the ABC transporters tested, MRP2 mRNA level was the highest found in human 
jejunum (Taipalensuu et a/., 2001 ). Also, MRP2 is able to transport anticancer drugs, 
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hence can also cause drug resistance like MRP1. Anticancer drugs that can be 
transported by MRP2 include methotrexate, vincristine, vinblastine, doxorubicin, 
epirubicin and possibly cisplatin and etoposide. Moreover, there is a fairly extensive 
overlapping of distribution as well as substrate specificity between MRP2 and P-gp. 
Hence, it is likely that these two proteins have considerable overlap in pharmacological 
as well as toxicological protective functions (Mottino eta/., 2000). 
Breast cancer-resistance protein (BCRP), a 'half-transporter', which belongs to the ABC 
White family, was first identified and isolated from the human MCF-7 breast cancer cells 
by Doyle et a/. (1998). Similar to P-gp and MRPs, BCRP was also found to be 
expressed in small intestine, colon and hepatocytes (AIIikmets et a/., 1998; Maliepaard 
et a/., 2001 ). Thus, it was postulated that BCRP might play a similar role to P-gp as well 
as MRPs in limiting oral drug bioavailability. BCRP was found to be able to expel a 
range of drugs such as topotecan, mitocantrone, doxorubicin and daunorubicin (Allen et 
a/., 1999; Maliepaard eta/., 1999; Robey eta/., 2001). 
In addition to the influx and efflux transporters, the intestinal epithelial cells are also rich 
in metabolising enzymes, especially those responsible for phase I oxidative metabolism, 
i.e. the cytochrome P450 superfamily (Mayersohn, 2002) although their level is lower 
than in liver (de Waziers et a/., 1990; Shimada et a/., 1994). The most abundant 
isoenzyme of the cytochrome P450 in human small intestine is CYP3A, being as high as 
80 to 100% of the amount found in the liver (de Waziers et a/., 1990; Kolars et a/., 
1992). Substrates of CYP3A may have poor bioavailability due to extensive intestinal 
and hepatic first-pass metabolism especially when it was later recognised that more 
than 50% of orally administered drugs might be substrates of this enzyme (Benet eta/., 
1996). Due to overlapping substrate specificity and tissue distribution, it is conceivable 
that both P-gp and CYP3A could synergistically alter the oral bioavailability of a wide 
range of drugs (Wacher et a/., 1995; Schuetz et a/., 1996a; Watkins, 1997). 
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1.4.1 P-glycoprotein (P-gp) 
To date, 52 ABC genes have been verified by the Human Genome Organization 
(HUGO) (Shin eta/., 2003). One of the most widely studied membrane efflux transporter 
is P-glycoprotein (P-gp; also known as MDR1, ABCB1) which belongs to the multidrug 
resistance protein subfamily of the ABC transporter superfamily. P-gp was first 
discovered and isolated by Juliano and Ling (1976) from colchicine-resistant Chinese 
hamster ovary cells. P-gp is a 170 kDa phosphorylated and glycosylated 
transmembrane protein with 1280 amino acids, arranged in two homologous halves of 
610 amino acids each joined by a flexible linker consisting of 60 amin~ acids (Ambudkar 
et a/., 1999). 
The two MDR genes that encode P-gp in human are MDR1 and MDR2 (also known as 
MDR3), whereas there are three genes that encode rodent P-gp, which are mdr1 a, 
mdr1b and mdr2. Human MDR1 P-gp and rodent mdr1a/1b P-gp have been shown to 
confer multidrug resistance; whereas MDR2 P-gp in human and mdr2 P-gp in rodent are 
responsible for transporting cellular phospholipids (Gottesman and Pastan, 1993). 
Although P-gp tends to be over-expressed in tumour cells, it is also foUnd in normal cells 
such as at the apical surface of epithelial cells in the liver (bile caniliculi), columnar 
mucosal cells in small intestine, capillary endothelium of the brain and testes, brush 
border of the proximal renal tubule and ductile cells of pancreas (Cordon-Cardo et a/., 
1990; Gatmaitan and Arias, 1993; Lee eta/., 2001 ). The anatomical localisation of P-gp 
suggested that it can protect the body from toxic xenobiotics by excreting them into bile, 
urine, and intestinal lumen (Lin et a/., 1999). Mouly and Paine (2003) first reported that 
the expression of MDR1 P-gp increases from proximal to distal regions along the entire 
human small intestine. As for P-gp in rat intestine, it was later shown that the expression 
of mdr1 a mRNA was moderate in the duodenum and jejunum, maximal in the ileum and 
lower through the proximal to the distal colon (lida eta/., 2005). 
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Expression of P-gp in tumour cells results in active extrusion of a wide range of cancer 
chemotherapeutic drugs. Also, P-gp has been shown to transport a broad variety of 
pharmacological distinct agents used for treatment of hypertension, allergy, infection, 
immunosuppresion, inflammation and neurological disorders (Lum et a/., 1993; van 
Asperen et a/., 1997; Verschraagen et a/., 1999; Seeliq and Landwojtowicz, 2000). 
Reviews by Schinkel and Jonker (2003) and Chan et a/. (2004) reported that most 
substrates of P-gp are hydrophobic with molecular size ranging from less than 200 Da to 
almost 1900 Da, in addition to being amphipathic in nature. The list of substrates is 
being periodically expanded as more studies are being carried out. 
Studies to determine the possible substrates, inhibitors and inducers of P-gp have been 
extensively carried out due to the immense capability of P-gp in altering the substrate 
bioavailability. Lown eta/. (1997a) reported the potential of P-gp as a rate-limiting first-
pass elimination mechanism of cyclosporin in 19 patients. Common azole antifungals 
were reported by Wang et a/. (2002) to inhibit functions of P-gp. However, further 
investigation revealed that only itraconazole and ketoconazole were shown to inhibit P-
gp functions in vitro at 50% inhibitory concentrations (IC50) of approximately 2 and 6 1-1M, 
respectively; while fluconazole had no effect on functions of P-gp. In another report by 
Rebbeor and Senior ( 1998), using two in vitro A TPase assays, cardiovascular drugs, 
namely verapamil, diltiazem, nifedipine and quinidine were found to stimulate the 
ATPase activity of P-gp. Verapamil and quinidine stimulated maximum ATPase activity 
at 10 1-1M, while nifedipine and diltiazem at 30 1-1M and 100 1-1M, respectively. All these 
four drugs exhibited a biphasic effect on P-gp. Above the concentrations at which 
maximum ATPase activity was stimulated, there was a corresponding decrease in 
activity. Likewise, tamoxifen (antiestrogen), naloxone (morphine antagonist) and 
progesterone (natural steroid) have been shown to stimulate ATPase activity in the in 
vitro assays. 
18 
Due to the ability of P-gp to mediate the oral bioavailability of a wide range of structurally 
and functionally diverse drugs, a lot of literature on drug-drug interactions as a result of 
inhibition or induction of P-gp has been reported. Digoxin, which is poorly metabolised 
by human CYP3A but is a known substrate of P-gp has been used in many studies 
evaluating the inhibitory or induction effect of other drugs on P-gp (Salphati and Benet, 
1998; Westphal eta/., 2000; Katoh eta/., 2001; Drescher eta/., 2003; Cornaire eta/., 
2004). The action on P-gp by the other drugs will consequently modulate the 
bioavailability as well as the pharmacokinetics of digoxin. Ketoconazole was able to 
inhibit P-gp, thereby elevating the plasma digoxin concentration, and hence AUC by 4 to 
5 folds after oral and intravenous administration of digoxin (Salphati and Benet, 1998). 
Westphal et a/. (2000) reported significant increase in AUC of digoxin following oral co-
administration with 100 mg talinolol. However, the interaction between digoxin and 
talinolol was suggested to be attributed to the competition of the two substrates for 
intestinal P-gp rather than inhibition of P-gp by talinolol. In addition, rifampicin co-
administration with digoxin has resulted in a significant reduction in digoxin AUC, with 
rifampicin being an inducer of P-gp (Drescher eta/., 2003). 
Apart from drugs, excipients and surfactants used in pharmaceutical formulation have 
been shown to enhance absorption of P-gp substrate drugs. For example, Martin-
F acklam et a/. (2002) demonstrated the dose-dependence of Cremophor EL in 
enhancing the oral bioavailability of saquinavir. Cornaire et a/. (2004) further tested the 
abilities of Labrasol, lmwitor 742, Acconon E, Softigen 767, Cremophor EL, Miglyol, 
Solutol HS 15, sucrose monolaurate, Polysorbate 20, TPGS and Polysorbate 80 to alter 
the transport of digoxin and celiprolol through the inverted gut sac as well as their 
pharmacokinetic profiles in Sprague-Dawley rats. Although transports of digoxin and 
celiprolol were most effective with Labrasol and Softigen 767 respectively, in vivo 
studies showed no significant increase in the overall AUCs of digoxin and celiprolol in 
spite of other changes in the pharmacokinetic profiles. 
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Besides being saturable, P-gp transport can be modulated by the presence of inhibitors 
and inducers. Inhibition of P-gp could potentially result from either competition for drug 
binding sites, or inhibition of ATP hydrolysis (P-gp is an energy dependent efflux pump) 
(Tamai and Safa, 1991; Ramachandra et a/., 1998; Lin, 2003). On the other hand, 
induction of P-gp is associated with the involvement of steroid xenobiotic receptor 
(SXR), a member of the nuclear hormone receptor superfamily as reviewed by Mizuno 
et a/. (2003). In addition, canalicular P-gp can be induced by enhancing the intracellular 
trafficking through redistribution between membrane P-gp and intrahepatic pools 
(Synold et a/., 2001 ). Furthermore, in a review by Lin (2003), it was shown that induction 
of P-gp is dose- and tissue- dependent. 
There are an increasing number of studies reporting the use of P-gp inhibitors in 
' ·, 
improving oral drug bioavailability (only applicable for drugs which exhibited poor ' :, II 
'• 
bioavailability due to extensive efflux transport by P-gp because not all of the drugs 
known to be substrates of P-gp exhibit poor oral bioavailability) (Lin, 2003), as it has 
been postulated that inhibition of P-gp might improve intestinal absorption and tissue 
distribution while reducing the substrate metabolism and elimination. Nevertheless, a 
potent yet safe and effective P-gp inhibitor has yet to be identified for co-administration 
with poorly bioavailable P-gp substrate drugs for enhanced absorption. It is anticipated 
that proof-of-concept studies involving patients with concomitant administration of P-gp 
inhibitor could be realised to offer a novel strategy for improving oral drug absorption. 
1.4.2 Intestinal phase I metabolising enzyme, CYP3A 
To date, the human genome encodes 57 cytochrome P450 (CYP) proteins which are 
the predominant phase I drug metabolising enzymes (Shimada et a/., 1994). They 
represent a large superfamily of members with porphyrin haem compl.ex as the catalytic 
moiety flanked by different protein structures which impart selectivity against various 
substrates (Gonzalez, 1989). Up till now, the major drug metabolising isoenzymes of 
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human CYP family identified are CYP1A2, 2A6, 2C8/9/10/19, 206, 2E1 and 3A4; 
CYP3A is the primary CYP subfamily among these isoforms (Shimada et a/., 1994; 
Nelson eta/., 1996; Smith eta/., 1998). 
Besides being localised in the liver where the major first-pass metabolism occurs, CYP 
enzymes are also found abundant in the small intestine, colon, pancreas and kidney 
(Kolars eta/., 1992; Shimada eta/., 1994). CYP enzymes are expressed in the villus tip 
of enterocytes of the GIT, in which CYP3A is the most abundant in human GIT, 
accounting for more than 70% of small intestine CYP (Watkins eta/., 1987). However, 
expression of CYP3A is highly variable among individuals, with 30 folds variation 
reported for the small intestine (Wacher et a/., 1998). Besides that, expression of 
CYP3A is not homogenous in the small intestine, exhibiting a significant gradient, being 
highest in the duodenum and lower towards distal ileum (de Waziers et a/., 1990; 
Thummel et a/., 1997). It is believed that hepatic and intestine CYP3A are of the same 
isoforms as the cDNAs of CYP3A i'n both locations are identical (Lown et a/., 1998) but 
not coordinately regulated (von Richter et a/., 2004). Therefore, it is evident that 
intestinal first-pass metabolism is also regarded as a major determinant of systemic 
bioavailability of orally administered drugs (Wacher eta/., 1998). 
Similar to P-gp, CYP3A exhibited broad substrate specificity. As m~ntioned earlier in 
section 1.4, as high as 50% of orally administered drugs may be substrates of this 
enzyme. Hence, the importance of CYP3A was accounted with respect to their action, 
duration and disposition on drugs and the metabolites (Gibson et a/., 2002). Like P-gp, 
besides being saturable, CYP3A can also be inhibited or induced by a number of 
structurally unrelated compounds. 
When rifampicin (a CYP3A inducer) was co-administered with cyclosporin (a known 
substrate of CYP3A), Hebert et a/. (1992) reported that cyclosporin clearance was 
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When rifampicin (a CYP3A inducer) was co-administered with cyclosporin (a known 
substrate of CYP3A), Hebert et a/. (1992) reported that cyclosporin clearance was 
increased while half life, bioavailability and Cmax were decreased. In contrast, when co-
administered with an inhibitor of CYP3A, ketoconazole, the oral bioavailability of 
cyclosporin obtained was 56% compared to 22% without ketoconazole co-administration 
(Gomez et a/., 1995). Apart from being a substrate, cyclosporin also exhibit inhibitory 
effect on CYP3A when it was reported to decrease the extraction ratio of midazolam and 
felodipine to 60% and 46% respectively in CYP3A-transfected Caco-2 cells (Benet eta/., 
2004). In another report by Li et a/. (2002), ketoconazole was also found to decrease 
the metabolism of indinavir by CYP3A. 
The inhibition and induction of CYP3A by a wide range of therapeutic agents have led to 
many drug-drug interactions being reported. Apart from drugs, food or herb constituents 
have also been shown to inhibit or induce CYP3A, resulting in food- or herb-drug 
interactions. Further discussion on· the food- and herb-drug interactions will be 
elaborated in section 1.5. 
1.4.3 Interactions between gastrointestinal P-gp and CYP3A 
Due to overlapping substrate specificity and tissue distribution, together with co-
inducibility of both P-gp and CYP3A, these two proteins act synergistically in altering the 
oral bioavailability of their substrate drugs (Benet et a/., 1999; Yumoto et a/., 1999; 
Cummins eta/., 2002; Mizuno eta/., 2003; Benet eta/., 2004). Besides being localised 
closely in the enterocytes, both genes encoding P-gp and CYP3A are also found on the 
same chromosome in close proximity, i.e. 7q21.1 for MDR1 (P-gp) while 7q22.1 for 
CYP3A (Watkins, 1997; Bertz and Granneman, 1997; Ishikawa eta/., 2004). 
Several proposed synergistic mechanisms of P-gp and CYP3A in limiting the oral drug 
bioavailability are briefly summarised as follows (Watkins, 1997): 
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i) P-gp, located at the apical brush border membrane may control the total drug 
transport across the epithelial cells by extruding the drug back into the 
gastrointestinal lumen while ensuring CYP3A is not being saturated. 
ii) P-gp may prolong the residence time of drugs in the enterocytes through the 
repeated process of extrusion and reabsorption, hence increasing the extent 
of exposure to intestinal metabolisms by CYP3A 
iii) In addition, P-gp may also selectively extrude metabolites from within the 
enterocytes where the metabolites are also substrate of CYP3A 
In vitro studies using L-MDR1, LLC-PK1 and Caco-2 cells as well as in vivo studies 
using mdr1 a deficient mice were carried out by Kim et a/. (1999) to evaluate the 
potential of some established CYP3A substrates as inhibitors and substrates of P-gp. 
However, it was discovered that not all substrates of CYP3A were substrates of P-gp. 
Nifedipine and midazolam were only substrates of CYP3A whereas terfenadine, 
erythromycin and lovastatin were shown to be substrates of both CYP3A and P-gp. Kim 
eta/. (1999) also revealed that transport of digoxin in Caco-2 cell was increased in the 
presence of PSC-833, quinidine, verapamil, ketoconazole and terfenadine, suggesting 
that these substrates of CYP3A might be inhibitors of P-gp. Following that, Katoh et a/. 
(2001) correlated the inhibitory effect of CYP3A substrates and their metabolites on P-
gp-mediated transport. They found that the transport of [3H]digoxin in the LLC-GA5-
COL 150 cells was strongly inhibited by amiodarone, desethylamiodarone (metabolite of 
amiodarone), azelastine and demethylazelastine (metabolite of azelastine) at IC5o 
values of 45.6, 25.2, 30.0 and 41.8 IJM, respectively. 
Tacrolimus is a potent immunosuppressive macrolide lactone showing poor oral 
bioavailability, which may be attributed to incomplete absorption, nutrient intake, 
concomitant medications, metabolism by CYP3A in liver and gut and/or alteration of P-
gp-mediated drug efflux. Other than co-administration of digoxin, 2-fold increase in 
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bioavailability of tacrolimus was also reported by Floren eta/. (1997) when ketoconazole 
was co-administered. Besides that, the efflux of indinavir (peptidomimetic HIV protease 
inhibitor) a known substrate of P-gp and CYP3A, in the Ussing Chamber system was 
significantly altered by verapamil and cyclosporin at a rate of 37 and 38%, respectively 
(Li eta/., 2002). 
Cummins et a/. (2002) reported that inhibition of both P-gp and CYP3A by cyclosporin 
resulted in a decreased extraction ratio of midazolam to 60% and felodipine to 46% 
(both are substrates of only CYP3A but not P-gp). For bisubstrates of P-gp and CYP3A, 
i.e. K77 and sirolimus, greater decrease in extraction ratio to 74 and .. 83%, respectively 
was achieved, revealing the synergistic effect of P-gp and CYP3A. These findings 
suggested that P-gp can increase the exposure of drugs to intestinal CYP3A by 
repeated efflux and reabsorption of drugs in the GIT. In another study using the rat 
single-pass intestinal perfusion model, Cummins et a/. (2003) again substantiated the 
role of P-gp in modulating the extent "Of intestinal metabolism by regulating drug access 
to the enzyme. 
Since there are many overlapping substrates/inhibitors/inducers b~tween P-gp and 
CYP3A, simultaneous administration of their inhibitors or inducers might result in drug-
drug interactions, leading to increased or decreased drug bioavailability. Besides being 
critical to older patients who usually receive multidrug therapy, such interactions are 
also given attention especially when drugs with narrow therapeutic indices are used. 
Induction of P-gp and CYP3A might lead to ineffective oral drug therapy due to high 
efflux as well as metabolism along the GIT. On the contrary, inhibition of P-gp and 
CYP3A might also be hazardous especially for drugs with narrow therapeutic indices 
whereby drugs may accumulate in the systemic circulation, exceeding the therapeutic 
window, hence causing toxicity. 
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